NanoMed is seeking additional funding from a private investor or group of investors to complete the on-going preclinical trials with its 5-FU prodrug nanomedicine and obtain regulatory approval for clinical trials with humans. The funds will be also used for further development of additional prodrug nanomedicines in NanoMed’s pipeline. One natural fit is an investor with direct experience in bio-medical/pharmaceutical translation.